Secretory leukocyte protease inhibitor suppresses the inflammation and joint damage of bacterial cell wall-induced arthritis
about
Secretory leukocyte protease inhibitor is an inducible antimicrobial peptide expressed in Staphylococcus aureus endophthalmitisGene expression profiles in the rat streptococcal cell wall-induced arthritis model identified using microarray analysis.Potential prognostic, diagnostic and therapeutic markers for human gastric cancerSecretory Leukocyte Protease Inhibitor Binds to Annexin II, a Cofactor for Macrophage HIV-1 InfectionSecretory Leukoprotease Inhibitor: A Native Antimicrobial Protein in the Innate Immune Response in a Rat Model ofS. aureusKeratitisAntimicrobial peptides in the female reproductive tract: a critical component of the mucosal immune barrier with physiological and clinical implicationsIncreased susceptibility to LPS-induced endotoxin shock in secretory leukoprotease inhibitor (SLPI)-deficient miceGene expression profile in rat small intestinal allografts after cold preservation/reperfusionBeneficial effects of secretory leukocyte protease inhibitor after spinal cord injury.The mouth: a gateway or a trap for HIV?Secretory leukocyte protease inhibitor mediates non-redundant functions necessary for normal wound healing.Stem cells for repair of cartilage and bone: the next challenge in osteoarthritis and rheumatoid arthritis.Regulation of progranulin expression in human microglia and proteolysis of progranulin by matrix metalloproteinase-12 (MMP-12).Aberrant host defense against Leishmania major in the absence of SLPI.Type II collagen degradation and its regulation in articular cartilage in osteoarthritisSecretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cellsSecretory leukocyte protease inhibitor (SLPI) expression and tumor invasion in oral squamous cell carcinomaModulation of granulocyte-endothelium interactions by antileukoproteinase: inhibition of anti-type II collagen antibody-induced leukocyte attachment to the synovial endothelium.The inhibitory effect of secretory leukocyte protease inhibitor (SLPI) on formation of neutrophil extracellular traps.Tumor necrosis factor-alpha (TNF-α) is a therapeutic target for impaired cutaneous wound healing.The secretory leukocyte protease inhibitor (SLPI) suppresses cancer cell invasion but promotes blood-borne metastasis via an invasion-independent pathway.Application of biomarkers in the clinical development of new drugs for chondroprotection in destructive joint diseases: a review.Expression of oral secretory leukocyte protease inhibitor in HIV-infected subjects with long-term use of antiretroviral therapy.Neutrophil elastase reduces secretion of secretory leukoproteinase inhibitor (SLPI) by lung epithelial cells: role of charge of the proteinase-inhibitor complex.Herpes simplex virus downregulates secretory leukocyte protease inhibitor: a novel immune evasion mechanismArthritis severity locus Cia4 is an early regulator of IL-6, IL-1β, and NF-κB activators' expression in pristane-induced arthritis.Inflammatory mediators and cartilage biomarkers in synovial fluid after a single inflammatory insult: a longitudinal experimental studyCollagen biomarkers for arthritis applications.The impact of IFN-γ receptor on SLPI expression in active tuberculosis: association with disease severity.WAP domain proteins as modulators of mucosal immunity.Secretory leukocyte protease inhibitor mediates proliferation of human endometrial epithelial cells by positive and negative regulation of growth-associated genes.Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer.Photodynamic antimicrobial chemotherapy for Staphylococcus aureus and multidrug-resistant bacterial burn infection in vitro and in vivo.Helicobacter pylori-induced downregulation of the secretory leukocyte protease inhibitor (SLPI) in gastric epithelial cell lines and its functional relevance for H. pylori-mediated diseases.Secretory leucoprotease inhibitor impairs Toll-like receptor 2- and 4-mediated responses in monocytic cells.Secretory leukocyte protease inhibitor inhibits neutrophil apoptosis.Paradoxical effects of tissue inhibitor of metalloproteinases 1 gene transfer in collagen-induced arthritis.Down-regulation of secretory leukocyte protease inhibitor expression in gastric mucosa is a general phenomenon in Helicobacter pylori-related gastroduodenal diseases.Antileukoproteinase: modulation of neutrophil function and therapeutic effects on anti-type II collagen antibody-induced arthritis.The secretory leukocyte protease inhibitor (SLPI) and the secondary granule protein lactoferrin are synthesized in myelocytes, colocalize in subcellular fractions of neutrophils, and are coreleased by activated neutrophils.
P2860
Q21342956-5C3D6948-385F-4A79-BD53-F1D0A29D3028Q24799004-EB1F082B-BE57-44AF-841C-D4838A025B90Q26866200-1587F56F-18C6-4A7C-9393-9D749E51B849Q27485184-4FDD8528-5AE1-4DFC-9CEA-15129F41AB1EQ27495900-D598CE83-409E-4755-A398-E5D3C6AC4842Q28087327-C9C49D35-EFF2-4D1C-BCE2-19D5833B46E1Q28588786-5A307B97-3094-46A2-9A98-66023DD1C093Q28645959-BFA9C1E3-01CA-4693-A0A0-293EBF7160EAQ33570020-6EEAE401-E0B9-4D3A-BCB9-7324A8F19987Q33874252-F2545B80-407B-490E-91B6-F1EFCA3A1F3EQ33920067-C5FA8DAE-9183-4059-83FF-4FCB30B5FB3CQ34180331-B57BBA8B-2294-4DA7-8DC2-9E41E6F87193Q34235574-EB4527C6-2C28-431A-995D-4DF1AAC1B15BQ34341332-C5759579-1295-459B-9267-8B25E6E8BADEQ34963140-AA098146-B081-46C4-9F6D-982D4925B059Q35022070-70972EA5-3EE3-418B-99D2-2DB0D4398FD7Q35071264-E5B6C4D1-547F-4FFB-B324-1A447A732623Q35605614-C8338606-A483-49A9-9BE2-21082F692267Q35741744-1AF8EB01-1B04-426A-8296-5D617764FC1CQ35779604-5ED45042-3860-43C8-9F2C-67E91A4B0333Q36190618-C3E3E248-45CB-400C-8D98-892C0AC8FF9DQ36631211-31DF5CDD-AC0F-4CDD-AF4F-BE6E41425B53Q36674118-1951D359-965B-4FB6-B5D5-666F9B9D3C3DQ36862444-F7BAEA9D-6FF0-4AD9-83D5-278EA7271546Q36898823-B85D7769-5515-411D-B9D9-27461F732D28Q37054708-6A866DA3-61CF-486A-BC8F-149215A1C348Q37206899-AE19FB7F-7B88-4DB3-B278-4F661A4AC27AQ37277952-BB985854-8A2C-495F-9689-06746017094CQ37734875-E13A69B1-777F-4A83-A00D-BE294977F0A7Q37936531-F528DC10-69F1-40F2-B535-EDCA54BF3B6CQ38289011-84597B9B-7575-44C0-810A-255542430950Q38794223-F474067D-ADD1-42AA-ADD5-617504A0F128Q40071674-5B6C2C45-F314-4827-B2FA-3C8740E5F56BQ40242898-44247295-8F70-45E1-AECA-A2FC050612A0Q40882951-BD3D670C-D988-450E-9E99-D4BAAAF76FFDQ43554883-8C16C33B-10D4-40BF-B1D0-C1B577D54EE9Q44017553-0807BC66-6B27-4B96-ADC2-74125D65E991Q44359066-3E851956-CAB5-4E8C-A647-1A0CCA4F10A1Q44973889-8BDD4887-D7CD-4D6F-AC82-B8604640DB96Q46745153-DF5AC375-7B00-441E-A4F6-77100923F6E7
P2860
Secretory leukocyte protease inhibitor suppresses the inflammation and joint damage of bacterial cell wall-induced arthritis
description
1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 1999
@ast
im August 1999 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 1999/08/16)
@sk
vědecký článek publikovaný v roce 1999
@cs
wetenschappelijk artikel (gepubliceerd op 1999/08/16)
@nl
наукова стаття, опублікована в серпні 1999
@uk
مقالة علمية (نشرت في 16-8-1999)
@ar
name
Secretory leukocyte protease i ...... al cell wall-induced arthritis
@ast
Secretory leukocyte protease i ...... al cell wall-induced arthritis
@en
Secretory leukocyte protease i ...... al cell wall-induced arthritis
@nl
type
label
Secretory leukocyte protease i ...... al cell wall-induced arthritis
@ast
Secretory leukocyte protease i ...... al cell wall-induced arthritis
@en
Secretory leukocyte protease i ...... al cell wall-induced arthritis
@nl
prefLabel
Secretory leukocyte protease i ...... al cell wall-induced arthritis
@ast
Secretory leukocyte protease i ...... al cell wall-induced arthritis
@en
Secretory leukocyte protease i ...... al cell wall-induced arthritis
@nl
P2093
P2860
P356
P1476
Secretory leukocyte protease i ...... al cell wall-induced arthritis
@en
P2093
A. R. Poole
D. E. Mizel
J. Thompson
R. C. Billinghurst
S. M. Wahl
P2860
P304
P356
10.1084/JEM.190.4.535
P407
P577
1999-08-16T00:00:00Z